Tuesday, July 25, 2017

Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs by KATIE THOMAS


By KATIE THOMAS

The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.

Published: July 24, 2017 at 08:00PM

from NYT Health http://ift.tt/2uvw3P1
via IFTTT




from WordPress http://ift.tt/2tIiKfl
via IFTTT

No comments:

Post a Comment